[In Process Citation]

Area of Science:

• Oncology
• Pharmacology
• Medical History

Background:

• Oncological therapeutic agent development is complex, costly, and time-consuming, with significant contributions from academic and public research institutions.
• Increasing regulatory demands since 1960 have amplified development timelines and costs in cancer drug discovery.
• German oncological research, initiated post-WWII, initially focused on ethyleneimino compounds before shifting to alkylating agents.

Purpose of the Study:

• To provide a historical overview of oncological therapeutic agent development in Germany.
• To highlight key milestones and discoveries in German cancer research, particularly in alkylating agents.
• To discuss the evolution of cancer therapies and ongoing research directions.

Main Methods:

• Historical review of oncological research and drug development in Germany.
• Analysis of key therapeutic agents, their development, and impact.
• Examination of regulatory influences on drug development costs and timelines.

Main Results:

• Development of significant alkylating cytotoxic agents, including cyclophosphamide, ifosfamide, and trofosfamide, by Asta-Werke.
• Introduction of mesna for organospecific detoxification, enhancing the safety and selectivity of oxazaophosphorine therapy.
• Ongoing research into novel alkylating agents and new therapeutic principles like hormonal agents.

Conclusions:

• German institutions have played a pivotal role in developing foundational cancer therapies, particularly alkylating agents.
• The development of supportive agents like mesna has significantly improved patient outcomes and treatment safety.
• Continued innovation in oncological research, including new drug classes, is crucial for advancing cancer treatment.